Methods and compositions for inhibiting oxidative stress
AssigneePresident and Fellows of Harvard College
InventorsConstance L. Cepko, Wenjun Xiong
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.
Claims18
A method for treating or preventing retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
- wherein the pharmaceutical composition comprises a recombinant adeno-associated virus (AAV) comprising a promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for promoting photoreceptor survival and/or function and a pharmaceutically acceptable carrier for intraocular administration,
- wherein the promoter is a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter,
- wherein the recombinant AAV is an AAV8 or AAV 2/8 recombinant AAV, and
- wherein the pharmaceutical composition is formulated for intraocular administration, thereby treating or preventing retinitis pigmentosa in the subject.
A method for treating or preventing retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
- wherein the pharmaceutical composition comprises an adeno-associated virus (AAV) comprising a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for prolonging the viability of a photoreceptor cell, and a pharmaceutically acceptable carrier for intraocular administration,
- wherein the pharmaceutical composition is formulated for intraocular administration, thereby treating or preventing retinitis pigmentosa in the subject.
A method for prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
- wherein the pharmaceutical composition comprises a recombinant adeno-associated virus (AAV) comprising a promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for promoting photoreceptor survival and/or function and a pharmaceutically acceptable carrier for intraocular administration,
- wherein the promoter is a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter,
- wherein the recombinant AAV is an AAV8 or AAV 2/8 recombinant AAV, and
- wherein the pharmaceutical composition is formulated for intraocular administration, thereby prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in the subject.
A method for prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
- wherein the pharmaceutical composition comprises an adeno-associated virus (AAV) comprising a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for prolonging the viability of the photoreceptor cell, and a pharmaceutically acceptable carrier for intraocular administration,
- wherein the pharmaceutical composition is formulated for intraocular administration, thereby prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in the subject.
Dependencies are inferred from the claim text.